US FDA Says Data Integrity Remains Challenging For API Manufacturers
Executive Summary
Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.
You may also be interested in...
Could Sponsors’ Supply Chain Policing Have Caught Alleged CRO Fraud?
The US FDA always encourages sponsors to ensure their suppliers and contractors are following the law, but agency inspectors may have been the only ones who could have discovered the data integrity problems that forced the downgrading of more than 100 generic drug applications.
Oncology Dominant As Japan Maintains Approvals Pace
Despite the emergence of the coronavirus pandemic at the end of the period, Japan’s regulatory authorities maintained an annual pace of new drug approvals on a par with the previous year, with expedited programs helping several drugs to market.
First-Ever OTC Inspections Drove Surge Of FDA Warning Letters In FY 2019
The good news: 75% of never-before-inspected firms complied with US drug GMP requirements. The bad news: 25% did not.